Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK has disclosed transactions involving senior management under its Deferred Investment Award Programme, following the vesting of the final 25% of awards granted in February 2021. Chief executive officer Luke Miels and ViiV Healthcare CEO and GSK Global Health president Deborah Waterhouse are each due cash payments linked to 24,979.493 notional ordinary shares, while global supply chain president Regis Simard will receive a payment tied to 12,489.746 notional shares.
The payments, calculated at £21.68 per notional share and subject to tax withholding, highlight GSK’s ongoing use of deferred, share-linked incentives to reward and retain top executives. These disclosures provide investors with visibility into the scale and structure of leadership compensation, underlining the company’s alignment of management rewards with its share performance over the vesting period.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £22.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company that focuses on uniting science, technology, and talent to develop medicines and vaccines aimed at getting ahead of disease. The group operates worldwide with a portfolio spanning vaccines, specialty, and general medicines, serving both developed and emerging healthcare markets.
Average Trading Volume: 8,443,303
Technical Sentiment Signal: Buy
Current Market Cap: £88.68B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.